Monahan Joseph has filed 35 insider transactions across 1 company since February 2024.
Most recent transaction: a option exercise of 50000 shares of Aclaris Therapeutics, Inc. ($ACRS) on March 01, 2025.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 1, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Monahan Joseph | Chief Scientific Officer | M | Common Stock | 50000 | $0.00 | 282,188.0000 | 77,296,665 | 21.53% | 0.06% |
| March 1, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Monahan Joseph | Chief Scientific Officer | M | Common Stock | 10925 | $0.00 | 293,113.0000 | 77,296,665 | 3.87% | 0.01% |
| March 1, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Monahan Joseph | Chief Scientific Officer | F | Common Stock | 27258 | $1.99 | 265,855.0000 | 77,296,665 | 9.30% | 0.04% |
| March 1, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Monahan Joseph | Chief Scientific Officer | M | Restricted Stock Units | 50000 | $0.00 | 0.0000 | 77,296,665 | 100.00% | 0.06% |
| March 1, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Monahan Joseph | Chief Scientific Officer | M | Restricted Stock Units | 10925 | $0.00 | 10,925.0000 | 77,296,665 | 50.00% | 0.01% |
| Feb. 1, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Monahan Joseph | Chief Scientific Officer | M | Common Stock | 7500 | $0.00 | 228,755.0000 | 77,296,665 | 3.39% | 0.01% |
| Feb. 1, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Monahan Joseph | Chief Scientific Officer | M | Common Stock | 14750 | $0.00 | 243,505.0000 | 77,296,665 | 6.45% | 0.02% |
| Feb. 1, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Monahan Joseph | Chief Scientific Officer | F | Common Stock | 11317 | $2.48 | 232,188.0000 | 77,296,665 | 4.65% | 0.01% |
| Feb. 1, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Monahan Joseph | Chief Scientific Officer | M | Restricted Stock Units | 7500 | $0.00 | 15,000.0000 | 77,296,665 | 33.33% | 0.01% |
| Feb. 1, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Monahan Joseph | Chief Scientific Officer | M | Restricted Stock Units | 14750 | $0.00 | 44,250.0000 | 77,296,665 | 25.00% | 0.02% |
| Feb. 3, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Monahan Joseph | Chief Scientific Officer | A | Restricted Stock Units | 83900 | $0.00 | 83,900.0000 | 77,296,665 | 9999.99% | 0.11% |
| Feb. 3, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Monahan Joseph | Chief Scientific Officer | A | Employee Stock Option (Right to Buy) | 293500 | $0.00 | 293,500.0000 | 77,296,665 | 9999.99% | 0.38% |
| Dec. 31, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Monahan Joseph | Chief Scientific Officer | M | Common Stock | 73750 | $0.00 | 245,726.0000 | 71,381,731 | 42.88% | 0.10% |
| Dec. 31, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Monahan Joseph | Chief Scientific Officer | F | Common Stock | 32937 | $0.00 | 212,789.0000 | 71,381,731 | 13.40% | 0.05% |
| Jan. 2, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Monahan Joseph | Chief Scientific Officer | M | Common Stock | 17380 | $0.00 | 230,169.0000 | 77,296,665 | 8.17% | 0.02% |
| Jan. 2, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Monahan Joseph | Chief Scientific Officer | F | Common Stock | 8914 | $0.00 | 221,255.0000 | 77,296,665 | 3.87% | 0.01% |
| Dec. 31, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Monahan Joseph | Chief Scientific Officer | M | Restricted Stock Units | 73750 | $0.00 | 73,750.0000 | 71,381,731 | 50.00% | 0.10% |
| Jan. 2, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Monahan Joseph | Chief Scientific Officer | A | Restricted Stock Units | 52667 | $0.00 | 52,667.0000 | 77,296,665 | 9999.99% | 0.07% |
| Jan. 2, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Monahan Joseph | Chief Scientific Officer | M | Restricted Stock Units | 17380 | $0.00 | 35,287.0000 | 77,296,665 | 33.00% | 0.02% |
| Dec. 10, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Monahan Joseph | Chief Scientific Officer | G | Common Stock | 15000 | $0.00 | 171,976.0000 | 71,381,731 | 8.02% | 0.02% |
| March 1, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Monahan Joseph | Chief Scientific Officer | M | Common Stock | 50000 | $0.00 | 184,834.0000 | 69,808,855 | 37.08% | 0.07% |
| March 1, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Monahan Joseph | Chief Scientific Officer | F | Common Stock | 14569 | $1.24 | 170,265.0000 | 69,808,855 | 7.88% | 0.02% |
| March 1, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Monahan Joseph | Chief Scientific Officer | M | Common Stock | 10925 | $0.00 | 181,190.0000 | 69,808,855 | 6.42% | 0.02% |
| March 1, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Monahan Joseph | Chief Scientific Officer | F | Common Stock | 3183 | $1.24 | 178,007.0000 | 69,808,855 | 1.76% | 0.00% |
| March 2, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Monahan Joseph | Chief Scientific Officer | M | Common Stock | 12500 | $0.00 | 190,507.0000 | 69,808,855 | 7.02% | 0.02% |
| March 2, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Monahan Joseph | Chief Scientific Officer | F | Common Stock | 3531 | $1.24 | 186,976.0000 | 69,808,855 | 1.85% | 0.01% |
| March 1, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Monahan Joseph | Chief Scientific Officer | M | Restricted Stock Units | 50000 | $0.00 | 50,000.0000 | 69,808,855 | 50.00% | 0.07% |
| March 1, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Monahan Joseph | Chief Scientific Officer | M | Restricted Stock Units | 10925 | $0.00 | 21,850.0000 | 69,808,855 | 33.33% | 0.02% |
| March 2, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Monahan Joseph | Chief Scientific Officer | M | Restricted Stock Units | 12500 | $0.00 | 0.0000 | 69,808,855 | 100.00% | 0.02% |
| Feb. 1, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Monahan Joseph | Chief Scientific Officer | M | Common Stock | 7500 | $0.00 | 137,417.0000 | 69,808,855 | 5.77% | 0.01% |
| Feb. 1, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Monahan Joseph | Chief Scientific Officer | F | Common Stock | 2583 | $1.20 | 134,834.0000 | 69,808,855 | 1.88% | 0.00% |
| Feb. 1, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Monahan Joseph | Chief Scientific Officer | M | Restricted Stock Unit | 7500 | $0.00 | 22,500.0000 | 69,808,855 | 25.00% | 0.01% |
| Feb. 1, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Monahan Joseph | Chief Scientific Officer | A | Employee Stock Option (Right to Buy) | 206500 | $0.00 | 206,500.0000 | 69,808,855 | 9999.99% | 0.30% |
| Feb. 1, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Monahan Joseph | Chief Scientific Officer | A | Restricted Stock Units | 59000 | $0.00 | 59,000.0000 | 69,808,855 | 9999.99% | 0.08% |
| Feb. 1, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Monahan Joseph | Chief Scientific Officer | A | Restricted Stock Units | 147500 | $0.00 | 147,500.0000 | 69,808,855 | 9999.99% | 0.21% |